Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)

Genvoya

Generic name: Genvoya is a combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.

Brand names: Genvoya

Class: Complete combination tablets

Side-effects:

Common: Nausea.


Rare: Lactic acidosis, serious liver problems (the first two are most likely in very overweight women or those who have been taking Genvoya for a long time), worsening of hepatitis B when stopping Genvoya (see Notes), body fat redistribution, immune reconstitution inflammatory syndrome (IRIS), renal impairment, decreases in bone mineral density, mineralisation defects.

Dosage:

Tablet comprises 150mg elvitegravir, 150mg cobisistat, 200mg emtricitabine and 10mg tenofovir alafenamide (TAF).

Take one tablet once per day.

Notes:

Special monitoring may be needed in patients co-infected with HIV and hepatitis B as Genvoya is not licenced to treat the latter. If you are taking Genvoya and then stop, it could cause your hepatitis B to worsen.

Genvoya should be taken with food.

Genvoya is not taken with other HIV medication.

If you're taking Genvoya, do not take St John’s Wort (the herbal supplement).


*Last reviewed on 2/12/2016. Next review: 2/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM